| 1. |
国家卫生健康委办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第八版). 全科医学临继续教育, 2020, 18(9): 771-776.
|
| 2. |
Fang Q, Zhou C, Nandakumar KS, et al. Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. Mediators Inflamm, 2020, 2020: 3830212.
|
| 3. |
Coutant F, Miossec P. Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Curr Opin Rheumatol, 2020, 32(1): 57-63.
|
| 4. |
Favalli EG, Ingegnoli F, De Lucia O, et al. COVID-19 infection and rheumatoid arthritis: faraway, so close!. Autoimmun Rev, 2020, 19(5): 102523.
|
| 5. |
Cheng C, Li C, Zhao T, et al. COVID-19 with rheumatic diseases: a report of 5 cases. Clin Rheumatol, 2020, 39(7): 2025-2029.
|
| 6. |
Accortt NA, Lesperance T, Liu M, et al. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken), 2018, 70(5): 679-684.
|
| 7. |
Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis, 2011, 70(5): 785-791.
|
| 8. |
Abualfadl E, Ismail F, Shereef RRE, et al. Impact of COVID-19 pandemic on rheumatoid arthritis from a multi-centre patient-reported questionnaire survey: influence of gender, rural-urban gap and north-south gradient. Rheumatol Int, 2021, 41(2): 345-353.
|
| 9. |
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis, 2020, 79(7): 859-866.
|
| 10. |
Roongta R, Ghosh A. Managing rheumatoid arthritis during COVID-19. Clin Rheumatol, 2020, 39(11): 3237-3244.
|
| 11. |
COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders. National Institute for Health and Care Excellence. (2020-04-03)[2021-04-20]. https://www.nice.org.uk/guidance/NG167.
|
| 12. |
扶琼, 吕良敬. 疫情之下, 风湿免疫病合并呼吸道感染的应对策略. 上海医学, 2020, 43(2): 99-101.
|
| 13. |
湖北省医学会风湿免疫病凤凰汇, 湖北省风湿免疫科质量控制中心专家委员会. 2019 新型冠状病毒肺炎疫情期湖北风湿免疫病患者随访和感染防治的专家建议(试行第一版). 内科急危重症杂志, 2020, 26(2): 93-96.
|
| 14. |
World Health Organisation. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. (2020-04-19)[2021-04-20]. https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19.
|
| 15. |
Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. Arthritis Rheumatol, 2021, 73(2): e1-e12.
|
| 16. |
Russell B, Moss C, Rigg A, et al. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. Ecancermedicalscience, 2020, 14: 1023.
|
| 17. |
Misra DP, Agarwal V, Gasparyan AY, et al. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol, 2020, 39(7): 2055-2062.
|
| 18. |
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
|
| 19. |
Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxchloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med, 2020, 383(21): 2041-2052.
|
| 20. |
李树仁, 赵文静, 李健超, 等. 2021 年美国 NIH 发布的新型冠状病毒肺炎治疗指南与中国发布的新型冠状病毒肺炎治疗方案对比分析. 中国全科医学, 2021, 24(14): 1735-1744, 1763.
|
| 21. |
Thomas K, Vassilopoulos D. Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol, 2020, 31(Suppl 1): 129-136.
|
| 22. |
Tudesq JJ, Cartron G, Rivière S, et al. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmun Rev, 2018, 17(2): 115-124.
|
| 23. |
Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis, 2020, 79(5): 667-668.
|
| 24. |
Favalli EG, Ingegnoli F, Cimaz R, et al. What is the true incidence of COVID-19 in patients with rheumatic diseases?. Ann Rheum Dis, 2021, 80(2): e18.
|
| 25. |
Favalli EG, Monti S, Ingegnoli F, et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?. Arthritis Rheumatol, 2020, 72(10): 1600-1606.
|
| 26. |
Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis, 2020, 79(7): 851-858.
|
| 27. |
González-Castro A, Cuenca Fito E, Fernandez A, et al. Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease. Med Intensiva (Engl Ed), 2021: S0210-5691(21)00039-5.
|
| 28. |
Ignatius EH, Wang K, Karaba A, et al. Tocilizumab for the treatment of COVID-19 among hospitalized patients: a matched retrospective cohort analysis. Open Forum Infect Dis, 2020, 8(1): ofaa598.
|
| 29. |
Costantino F, Bahier L, Tarancón LC, et al. COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Joint Bone Spine, 2021, 88(1): 105095.
|
